A new FDA application for relacorilant shows promising survival benefits in treating platinum-resistant ovarian cancer, ...

Paclitaxel, often sold under the brand name Taxol, is one of the most widely prescribed chemotherapy drugs and is used to treat a variety of cancers, including breast, ovarian, and lung.

M Markman, BN Bundy, DS Alberts, etal : Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and ...

The launch of the lyophilized powder for injection containing 100 mg of paclitaxel in a single-dose vial for intravenous use follows approval by the FDA on Oct. 8, 2024.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

--Athenex, Inc.,, a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today ...

Topline data were announced from a phase 2/3 trial evaluating tovecimig in combination with paclitaxel in patients with unresectable advanced, metastatic or recurrent biliary tract cancers (BTC).

Paclitaxel Mortality No Longer the Main Question. After years of being the standard drug for DCBs in PAD treatment, a safety signal for paclitaxel emerged in 2018 from a meta-analysis that led to a ...

Among 494 patients who had undergone randomization, overall survival was significantly longer with trastuzumab deruxtecan than with ramucirumab plus paclitaxel (median, 14.7 vs. 11.4 months ...

The primary patency rates between sirolimus- and paclitaxel-treated patients at 12 months showed a difference of just 1.2%, with a P value for noninferiority of 0.022, Ulf Teichgräber, MD, (University ...